Investigators searched five databases (PubMed, ScienceDirect, IEEE Xplore, OpenAlex, Lens.org) on 15 March 2026 for studies published between January 2020 and March 2026. The authors did not prepare or register a protocol. Data extraction targeted clinical cohort evaluations that provided complete 2×2 contingency data and applied a microbiological or composite reference standard to all participants. Study quality was appraised with QUADAS-2 and certainty of evidence with GRADE.
The review ultimately included 21 studies reporting 26 evaluations of AI models for detection of pulmonary tuberculosis on chest X-ray. From those, nine evaluations drawn from three independent cohorts met criteria for the primary pooled analysis; overlapping participant sets were handled post hoc by selecting one evaluation per cohort for sensitivity analyses. The authors also noted that a subsequent PubMed search found additional eligible clinical evaluations that had not been screened, so the review is incomplete for those later reports.
The pooled analysis used a bivariate random-effects model and reported both 95% confidence intervals and 95% prediction intervals. Pooled sensitivity across the three cohorts was 0.896 (95% CI 0.874 to 0.915), with a prediction interval spanning 0.798 to 0.950. Pooled specificity was 0.689 (95% CI 0.642 to 0.732), prediction interval 0.499 to 0.831. Both pooled confidence intervals include the WHO triage thresholds of sensitivity 90% and specificity 70%.
When the authors added a screening study that had partial verification of reference testing, pooled specificity increased to 0.735. The review team emphasized that pooled estimates derive from only three cohorts, and that observed specificity varied by product and by setting. They therefore cautioned against generalizing a single diagnostic threshold across different clinical environments without local calibration.
Eighteen of 24 assessed evaluations were judged at high risk of bias using QUADAS-2 domains, the authors reported. Only one of the 21 included studies combined prospective cohort design, full verification of the reference standard for all participants, external validation and achievement of the WHO thresholds. The certainty of pooled evidence was graded as low for sensitivity and very low for specificity.
The review team also performed a post hoc analysis to account for overlapping participants between evaluations; they selected one evaluation per cohort to avoid double-counting. No further details on individual study sampling methods, population demographics, or model architecture and thresholds were reported in the abstract; the source did not provide those specifics in the summary text.
Data indicated that AI-CXR algorithms can approach the WHO sensitivity target for triage in clinical cohorts, while specificity is close to but not consistently above the WHO target. These findings suggest a potential role for AI as a standardized triage tool where radiology capacity is limited, but they also underline important caveats:
The authors therefore recommended that implementers validate algorithms prospectively in their own populations and set local thresholds before routine use. The review did not report implementation workflows, hardware requirements, or cost analyses; those details were not provided in the abstracted material.
The authors listed several concrete limitations. The pooled analysis covered only three independent cohorts, which limits the generalizability of pooled estimates. High risk of bias in most evaluated runs lowers confidence in pooled accuracy metrics. The certainty of evidence was graded low or very low, which affects the strength of any clinical recommendation. A subsequent search discovered additional clinical evaluations that the review did not screen; the authors therefore acknowledge the review is incomplete for those later studies.
Missing from the reported summary were granular details on study populations, individual model performance by product, threshold-setting procedures, and whether radiologist comparators were used within cohorts; the source did not report those specifics in its abstract. The authors ended by stating that prospective, externally validated studies that fully verify the reference standard for all participants are needed before broad deployment of AI-CXR for pulmonary tuberculosis screening and triage. That statement frames the next clear research milestones: larger, well-verified cohorts; head-to-head external validations; and standardized reporting to reduce bias and improve certainty of evidence.